Nanotechnology Based Drug Delivery System in Tuberculosis: Review
Abstract
Full Text:
PDFReferences
Meena LS .Survival mechanisms of pathogenic Mycobacterium tuberculosis H37Rv. FEBS J (2010)277:2416–27.
Zumla A, Raviglione M, Hafner R, von Reyn CF. Current concepts. N Engl J Med(2013) 368:745–55.
Jeong YJ, Lee KS. Pulmonary tuberculosis: up-to-date imaging and management. Am J Roentgenol (2008) 191:834–44.
S. H. Kaufmann, “Fact and fiction in tuberculosis vaccine research: 10 years later,” The Lancet Infectious Diseases,(2011) vol. 11, no. 8, pp. 633–640.
Sarkar S, Suresh MR. An overview of tuberculosis chemotherapy – a literature review. J Pharm Pharm Sci (2011) 14:148–6.
Singh J ,Garg T, Rath G, Goyal A .Advances in nanotechnology-based carrier systems for targeted delivery of bioactive drug molecules with special emphasis on immunotherapy in drug resistant tuberculosis – a critical review. Drug Delivery (2015) 23:5,1676-1698.
Gupta P, Garg T, Tanmay M, Arora S. Polymeric drug-delivery systems: role in P-gp efflux system inhibition. Crit Rev Ther Drug Carrier Syst (2015) 32:247-75.
Gupta RK, Thakur TS, Desiraju GR, Tyagi JS . Structure-Based Design of DevR Inhibitor Active against Nonreplicating Mycobacterium tuberculosis. J. Med. Chem. (2009),52:6324-6334.
Mitchison, D. A. Basic mechanisms of chemotherapy. Chest (1979), 76, 771–781.
Zhang Y, Yew W. Mechanisms of drug resistance in Mycobacterium tuberculosis. In: Chiang CY, ed. State of the art series. Drug-resistant tuberculosis. Number 1 in the series. Int J Tuberc Lung Dis (2009) 13:1320-30.
Kochi A, Vareldzis B, Styblo K. Multidrug-resistant tuberculosis and its control. Res Microbiol (1993) 144:104-10.
Wade MM, Zhang Y. Mechanisms of drug resistance in Mycobacterium tuberculosis. Front Biosci (2004) , 9:975-94.
Mikusova K, Slayden RA, Besra GS, Brennan PJ. Biogenesis of the mycobacterial cell wall and the site of action of ethambutol. Antimicrob Agents Chemother (1995) 39:2484-9.
Zhang Y, Wade MM, Scorpio A, et al. Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid. J Antimicrob Chemother (2003),52:790-5.
Garg T, Rath G, Goyal AK. Colloidal drug delivery systems: current status and future directions. Crit Rev Ther Drug Carrier Syst (2015), 32:89–147.
Garg T, Rath G, Murthy RR, et al. Current nanotechnological approaches for an effective delivery of bioactive drug molecules to overcome drug resistance tuberculosis. Curr Pharm Des (2015), 21:3076-89.
Kaur G, Garg T, Rath G, Goyal AK. Archaeosomes: an excellent carrier for drug and cell delivery. Drug Deliv. (2015), doi:10.3109/10717544.2015.1019653.
Momoh M, Kenechukwu F, Attama A. Formulation and evaluation of novel solid-lipid microparticles as a sustained release system for the delivery of metformin hydrochloride. Drug Deliv (2013), 20:102-11.
Pandey R, Sharma S, Khuller G. Oral solid-lipid nanoparticlebased antitubercular chemotherapy. Tuberculosis (2005), 85:415–20.
Wang Y, Wu W. In situ evading of phagocytic uptake of stealth solid-lipid nanoparticles by mouse peritoneal macrophages. Drug Deliv (2006), 13:189–92.
Singh G, Pai RS. Pharmacokinetics and in vivo biodistribution of optimized PLGA nanoparticulate drug delivery system for controlled release of emtricitabine. Drug Deliv (2014), 21:627-35.
Banyal S, Malik P, Tuli HS, Mukherjee TK. (2013). Advances in nanotechnology for diagnosis and treatment of tuberculosis. Curr Opin Pulmon Med (2013), 19:289-97.
Parikh R, Patel L, Dalwadi S. Microparticles of rifampicin: comparison of pulmonary route with oral route for drug uptake by alveolar macrophages, phagocytosis activity and toxicity study in albino rats. Drug Deliv (2014), 21:406-11.
Sharma N, Mishra S, Sharma S, Deshpande RD, Sharma RK. reparation and Optimization of Nanoemulsions for targeting Drug Delivery Int. J. Drug Dev. & Res.,(2013),5(4): 37-48.
Thakur A, Walia MK, Kumar S. Nanoemulsion in enhancement of bioavailability of poorly soluble drugs: a review. Pharmacophore (2013), 4:15-25.
Bhatt P, Madhav S. (2011). A detailed review on nanoemulsion drug delivery system. Int J Pharm Sci Res (2011), 2:2292–8.
Setya S, Talegaonkar S, Razdan B. Nanoemulsions: formulation methods and stability aspects. World J Pharm Pharm Sci (2013), 3:2214-28.
Lifshitz IM, Slyozov VV. The kinetics of precipitation from supersaturated solid solutions. Journal of Physics and Chemistry of Solids (1961), 19:35–50.
Corswant CV, Thoren P, and Engstrom S. Triglyceride based microemulsion for intravenous administration of sparingly soluble substances. J Pharm Sci .(1998) 87:200–208 .
Nikonenko B, Reddy VM, Bogatcheva E, et al. Therapeutic efficacy of SQ641-NE against Mycobacterium tuberculosis. Antimicrob Agents Chemother(2014), 58:587–9.
Mushir A, Javed A Bali V. Study of surfactant combinations and development of a novel nanoemulsion for minimising variations in bioavailability of ezetimibe .Col. and Surf B: Biointerfaces (2010), 76:412.
Capek I. Degradation of kinetically-stable O/W emulsions . Review on mechanisms of destabilization of nano-emulsions. Adv in Colloid and Interf Sci (2004), 107:102-10.
Müller RH, Petersen RD, Hommos A, Pandeines RJ. Nanostructured lipid carriers (NLC) in cosmetic dermal products. Adv Drug Deliv Reviews (2007), 59:22–30.
Del Pozo-R A, Delgado D, SolinísMA, GascónAR, Pedraz JL. Solid lipid nanoparticles: factors affecting cells transfection capacity. Int. J. of Pharm. (2007),339:261-8.
Teeranaichaideekul V, Souto EB, Junyaprasert VB, Müller RH. Cetyl palmitate-based NLC for topical delivery of coenzyme Q10: development, physicochemical characterization and in vitro release studies. Eur. J. of Pharm and Biopharm (2007), 67:141-8.
Koroleva MYu, Yurtov EV .Nanoemulsions: the properties, methods of preparation and promising Applications . Russian Academy of Sciences and Turpion Ltd (2012), 81:1.
Porras M, Martínez A, Solans C, González C, Gutierrez JM. Ceramic particles obtained using W/Onano-emulsions as reactionmedia.Colloids and Surfaces A, Physicochemical and Engineering Aspects (2005), 270-271:189-94.
Singh G, Dwivedi H, Saraf SK, Saraf SA. Niosomal delivery of isoniazid-development and characterization. Trop J Pharm Res (2011), 10:203-10.
El-Ridy MS, Yehia SA, Kassem MA-E-M, et al. Niosomal encapsulation of ethambutol hydrochloride for increasing its efficacy and safety. Drug Deliv (2015), 22:21-36.
Sharma R, Mahatma R, Bharkatiya M, Goyal A. Niosomes – as potential drug delivery system. Int J Drug Res Technol (2012), 2:422-9.
Gagandeep Garg T, Malik B, Rath G, Goyal AK. (2014). Development and characterization of nano-fiber patch for the treatment of glaucoma. Eur J Pharm Sci (2014), 53;10-16.
Li X, Guo Q, Zheng X, et al. Preparation of honokiol-loaded chitosan microparticles via spray-drying method intended for pulmonary delivery. Drug Deliv (2009), 16:160–6.
Kaur P, Garg T, Vaidya B, et al . Brain delivery of intranasal in situ gel of nanoparticulated polymeric carriers containing antidepressant drug: behavioral and biochemical assessment. J Drug Target (2014), 23: 275–86.
Parikh R, Patel L, Dalwadi S. Microparticles of rifampicin: comparison of pulmonary route with oral route for drug uptake by alveolar macrophages, phagocytosis activity and toxicity study in albino rats. Drug Deliv (2014), 21:406-11.
Saraogi GK, Sharma B, Joshi B, et al. Mannosylated gelatine nanoparticles bearing isoniazid for effective management of tuberculosis. J Drug Target (2011), 19:219–27.
Dubey R. Pure drug nanosuspensions-Impact of nanosuspension technology on drug discovery and development. Drug Del Tech (2006), 6:65-71.
Barret ER. Nanosuspensions in drug delivery. Nat Rev. (2004), 3:785–96.
Patel VR, Agrawal YK. Nanosuspension: An approach to enhance solubility of drugs. J Adv Pharm Technol Res (2011), 2(2):81-87.
Arunkumar N, Deecaraman N, Rani C. Nanosuspension technology and its application in drug delivery. Asian J. of pharm. (2009), DOI: 10.4103/0973-8398.56293.
Peters K, Leitzke S, Diederichs J, et al. Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection. J Antimicrob Chemother (2000), 45:77-83.
Sharma R, Garg T, Goyal AK, Rath G. Development, optimization and evaluation of polymeric electrospun nanofiber: a tool for local delivery of fluconazole for management of vaginal candidiasis. Artif Cells Nanomed Biotechnol. [Epub ahead of print].(2014), doi:10.3109/21691401.2014.966194.
Veigas B, Doria G, Baptista PV. Nanodiagnostics for Tuberculosis, Understanding Tuberculosis Global Experiences and Innovative Approaches to the Diagnose, Dr. Pere-Joan Cardona (Ed.) ,(2012), ISBN: 978-953-307-938-7.
Chan, W.C.W., Maxwell, D.J., Gao, X., Bailey, R.E., Han, M., & Ni, S., Luminescent quantum dots for multiplexed biological detection and imaging, Current Opinion in Biotech (2002), 13,1:40-46.
Gazouli, M., Liandris, E., Andreadou, M., Sechi, L.A., Masala, S., Paccagnini, D., & Ikonomopoulos, J. Specific detection of unamplified Mycobacterial DNA by use of fluorescent semiconductor quantum dots and magnetic beads, J. of Clinical Micro (2010), 48, 8: 2830–2835.
Griffith, D.E., Aksamit, T., Brown-Elliott, B.A., Catanzaro, A., Daley, C., Gordin, F., Holland, S.M., Horsburgh, R., Huitt, G., Iademarco, M.F., Iseman, M., Olivier, K., Ruoss, S., von Reyn, C.F., Wallace, R.J., & Winthrop, K. An official ATS/IDSA statement: Diagnosis, treatment, and prevention of nontuberculous Mycobacterial diseases, Amer J. of Resp and Critical Care Med. (2007), 175: 367416.
Yashodhara B, Huat CB, Naik LN, et al. Multidrug and extensively drug-resistant tuberculosis from a general practice perspective. Infect Drug Resist (2010), 3:115-22.
Goyal G, Garg T, Rath G, Goyal AK. Current nanotechnological strategies for an effective delivery of drugs in treatment of periodontal disease. Crit Rev Ther Drug Carrier Syst(2014), 31: 89–119.
Gupta RK, Thakur TS, Desiraju GR, Tyagi JS . Structure-Based Design of DevR Inhibitor Active against Nonreplicating Mycobacterium tuberculosis. J. Med. Chem. (2009),52:6324-6334.
Refbacks
- There are currently no refbacks.